Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas

Table 3 Expression of biomarkers and HER2 gene status in BTC samples from patients.

Sample	EGFR	TGF-α	P-MAPK	P-AKT	PTEN	HER2	HER2 FISH *
1	0	0	-	-	1+	0	ND
2	3+	+	-	-	1+	0	ND
3	3+	+	-	-	1+	0	ND
4	3+	+	-	+	3+	0	ND
5	3+	+	-	-	ND	1+	ND
6	3+	+	-	-	1+	0	ND
7	3+	+	-	+	2+	0	ND
8	3+	+++	-	+	3+	0	ND
9	3+	0	-	-	1+	0	ND
10	3+	0	+	+	2+	0	ND
11	3+	+++	+	+	3+	1+	ND
12	0	0	-	-	ND	ND	ND
13	2+	+	+	+	2+	0	ND
14	3+	+	+	-	2+	3+	RATIO: 10
15	2+	+	-	-	1+	2+	1.4 POLYSOMY 17
16	1+	0	-	-	1+	0	ND
17	0	0	-	-	1+	2+	1.7 POLYSOMY 17
18	2+	+	-	+	1+	0	ND
19	0	0	+	+	ND	2+	RATIO: 5.9
20	0	0	ND	ND	3+	0	ND
21	1+	++	+	+	3+	ND	ND
22	0	0	-	-	3+	0	ND
23	0	0	-	+	3+	0	ND
24	1+	+++	+	+	3+	0	ND
25	3+	+	+	+	1+	0	ND
26	0	0	-	+	3+	0	ND
27	0	0	+	-	3+	ND	ND
28	0	0	-	-	3+	0	ND
29	0	+	+	-	2+	0	ND
30	0	+	-	+	1+	3+	RATIO: 6.9
31	3+	0	+	+	3+	ND	ND
32	0	ND	+	-	2+	0	ND
33	3+	0	+	+	3+	0	ND
34	3+	+	-	+	3+	0	ND
35	3+	+	+	+	2+	ND	ND
36	3+	+	+	+	3+	ND	ND
37	3+	+++	+	+	2+	ND	ND
38	1+	++	ND	ND	2+	0	ND
39	3+	+	+	+	ND	0	ND
40	0	0	+	+	ND	0	ND
41	2+	+	ND	ND	2+	ND	ND
42	3+	+	ND	ND	3+	0	ND
43	0	0	-	-	3+	0	ND
44	0	0	+	-	2+	0	ND
45	3+	+	+	+	1+	0	ND
46	3+	+	-	+	3+	0	ND
47	2+	++	+	+	1+	ND	ND
48	2+	+	+	+	1+	ND	ND
49	0	0	-	-	3+	0	ND

ISSN: 1471-2407